11-MD, PhD, MBA, King Faisal Specialist Hospital & RC, Jeddah, Saudi Arabia
Mohammed Omar Galal , MD, PhD, MBA, King Faisal Specialist Hospital & RC, Jeddah, Saudi Arabia , firstname.lastname@example.org
Pulmonary hypertension (PHT) has classically been treated with expensive vasodilators. Through the treatment of hypoxia-induced PHT as well as postoperative hypoxia by proxy PHT, possible alternatives in treatment have been discovered. Results of the aforementioned treatments and patient interventions have been discussed in this paper. Medications discussed individually are MgSO4, ACE inhibitors, and alpha blockers as well as their implementation in therapeutic regimens. The conclusions drawn from those largely successful interventions lead to a proposal for the development of an alternative medication for the hypoxia-induced pulmonary hypertension that theoretically would prove to be as inexpensive as it would be effective. Bringing together the results of the aforementioned research, this medication would consist of MgSO4, ACE Inhibitors, and alpha blockers. It is inferred that a triple therapy of the three drugs would allow for synergistic effects and reduce the side effects to a minimum. The goal would be to develop a medication that can be used for all the communities where it is needed, regardless of their medical development or financial flexibility.